ISAR abstract titles...International Society for Antiviral Research...In May...New Orleans this one has bio's presenting...
Synergistic Inhibition of Replication of BVDV by PG 301029 Used in Combination with Ribavirin or Ribavirin and Interferon.
R.W. Buckheit, Jr. and T.L. Brenner.
GeneLogic, Inc., Gaithersburg, Md.; and University of Arizona College of Pharmacy,Tucson, Ariz., USA.
64. In Vitro Combination Studies of VX-950 (a HCV Protease Inhibitor) or VX-497 (an IMPDH Inhibitor), Two Novel Anti-HCV Clinical Candidates, with IFN-a.
K. Lin, C. Lin, and A.D. Kwong.
Vertex Pharmaceuticals, Inc., Cambridge, Mass.,USA.
65. Clinical Evaluation of a Human Monoclonal Antibody Against the Envelope Protein(E2) of HCV for Prevention of HCV Infection.
E. Ilan, A. Zauberman, N. Graham, O. Nussbaum, D. Terkieltaub, E. Galun, N. Terrault, R. Eren, and S. Dagan.
XTL Biopharmaceuticals, Ltd., Rehovot; Hadassah University Hospital; and University of California at San Francisco, Calif., USA.
Oral Session VI: Hepacivirus Infections
Chairpersons: Craig Gibbs and Johan Neyts
8:30am Plenary Speaker
Stanley Lemon, University of Texas Medical Branch, Galveston, Tex., USA
“Impact of Specific Antiviral Therapy on Hepatitis C Virus Suppression of Host Cell Defenses”
9:00 140. HCV NS3 Protease and NS5B Polymerase Inhibitors as Antiviral Agents.
P.L. Beaulieu.
Boehringer Ingelheim (Canada), Ltd., Laval,QuÈbec,
9:15 141. Inhibition of Heptitis C Virus RNA Replication by Benzimidazoles with High Affinity for the 5'-Untranslated Region of the Genomic RNA.
E.E. Swayze, P. Seth, E.A. Jefferson, A. Miyaji, S. Osgood, R. Ranken, S. Propp, K. Lowery, and R.H. Griffey.
Ibis Therapeutics, Carlsbad, Calif., USA.
9:30 142. Nucleoside Inhibitors of HCV Replication and the Corresponding Nucleoside Triphosphate Inhibitors as Chain Terminators of HCV NS5B Polymerase.
L. Lou, C. Hancock, D. Latour, J. Pouliot, C. Roberts, J. Keicher, N. Dyatkina, R.Griffith, U. Schmitz, and E. Michelotti.
Genelabs Technologies, Inc., Redwood City, Calif.,
9:45 143. In-Vitro and In-Vivo Evaluation of HCV Polymerase Inhibitors as Potential Drug Candidates for Treatment of Chronic Hepatitis C Infection.
E. Ilan, A. Zauberman, S. Aviel, O. Nussbaum, E. Arazi, O. Ben-Moshe, D. Slama, I. Tzionas, Y. Shoshany, S.-W. Lee, J.-J. Han, S.-J. Park, G.-H. Lee, E.-Y. Park, J.-C. Shin, J.-W. Shu, J.-W. Kim, and S. Dagan.
XTL Biopharmaceuticals, Ltd., Rehovot, Israel; B&C Biopharm; and Myong Ji University, Korea.
10:00 Break(whew!)
10:30 144. Susceptibility of Different Genotypes of Hepatitis C Virus to Inhibition by Nucleoside and Nonnucleoside Inhibitors.
S. Carroll, C. Bailey, M. Bosserman, C. Burlein, A. Simcoe, J. Fay, S. Ludmerer, D. Graham, R. LaFemina, O. Flores, D. Hazuda, S. Altamura, G. Migliaccio, L.Tomei, R. De Francesco, V. Summa, and D. Olsen.
Merck Research Laboratories, West Point, Pa., USA; and Instituto Ricerche di Biologia Molecolare, Merck Research Laboratories, Pomezia, Italy.
10:45 145. Comparison of Two Anti-HCV Clinical Candidates, VX-950 and BILN 2061, for Potency and Resistance in the HCV Replicon System and in a Novel HCV Protease Animal Model.
K. Lin, C. Lin, G. Kalkeri, S. Almquist, Y.-P. Luong, B.G. Rao, Y. Wei, C.A. Gates, R.B. Perni, and A.D. Kwong.
Vertex Pharmaceuticals, Inc., Cambridge, Mass.,
11:00 146. Gene Expression Patterns During Anti-HCV Treatment with Interferons and Interferon Combinations in the HCV Replicon Model.
B. Korba, C. Okuse, and J. Rinaudo.
Georgetown University, Rockville, Md., USA. |
